Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.Design, Setting, and Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021. Data extraction and analysis were conducted between September 2023 and August 2024.Exposure: A diagnosis of lung cancer, liver cancer, stomach cancer, colorectal cancer, pancreatic cancer, prostate cancer, gallbladder and biliary tract cancer, breast cancer, non-Hodgkin lymphoma, leukemia, or multiple myeloma.Main Outcomes and Measures: The use of broad-spectrum antibiotics (ie, antipseudomonal β-lactams, carbapenems, or glycopeptides) was evaluated using 2 metrics according to end-of-life trajectory: (1) prescription proportion (percentage of patients receiving antibiotics) and (2) consumption amount (days of therapy per 1000 patient-days). The end-of-life trajectory was divided into 5 intervals: T1 (6 months to 3 months before death), T2 (3 months to 1 month before death), T3 (1 month to 2 weeks before death), T4 (2 weeks to 1 week before death), and T5 (final week before death). Logistic regression was performed to calculate odds ratios and 95% CIs for antibiotic prescription proportion without adjustment for multiple comparisons, and Poisson regression was used to calculate adjusted relative risks.Results: Among the 515 366 decedents included, the mean (SD) age was 68.8 (11.7) years, and 347 327 (67.4%) were male. A total of 483 405 patients (93.8%) had solid tumors, with lung cancer (122 142 patients [23.7%]) being the most common type. Overall, 288 151 patients (55.9%) received broad-spectrum antibiotics during the last 6 months of life. The proportion of patients receiving broad-spectrum antibiotics peaked during T2, with 144 920 (28.1%) receiving at least 1 dose, and declined to 68 564 (13.3%) during T5. In contrast, total consumption peaked during T3, reaching 190.0 days of therapy per 1000 patient-days. These patterns were consistent across antibiotic classes and cancer types. During the last week of life, patients with leukemia had the highest exposure to broad-spectrum antibiotics compared with those with lung cancer, both for prescription proportions (crude odds ratio, 1.50; 95% CI, 1.43-1.58) and total consumption (adjusted relative risk, 1.21; 95% CI, 1.19-1.23).Conclusions and Relevance: In this cohort study of patients with advanced cancer, broad-spectrum antibiotic use increased from 3 months to 2 weeks before death, suggesting that this may be a key period for optimizing use and aligning care with patient goals.